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Molecular Detection and Characterization of Human 
Metapneumovirus (hMPV) in Hospitalized Children Residing in 
Southern Palestine 
Nabil Rishmawi 
ABSTRACT 
The recent discovery of Human Metapneumovirus (hMPV) by Van Den Hoogen 
from the Netherlands in 2001 has added a new member to the group of viruses which 
can cause respiratory tract infections. hMPV is a pleomorphic enveloped virus which 
contains single-stranded RNA with negative polarity.  hMPV has been classified in 
the Paramyxoviridae family. Since its discovery, both hMPV lineages A and B and 
their sub-lineages have been reported in many parts of the world with a detection rate 
between 2-25%.  Moreover, hMPV has been reported to be associated with 
respiratory tract illness in children less than 5 years of age.  
In this study, we investigated the frequency of hMPV in 790 nasopharyngeal 
aspirates of Palestinian children, age one day to 13 years, hospitalized at Caritas 
Baby hospital between November 2005 and October 2006. Viral RNA was extracted 
using QIAamp RNA extraction kit (Qiagen GmbH, Hilden, Germany), and amplified 
for hMPV using an in-house RT-PCR assay. Moreover 1019 bp from the N gene was 
amplified and partially sequenced in order to perform phylogenetic analysis.  
hMPV was detected in 251 (31.8%) of the patients samples analyzed.   This 
positivity rate was one of the highest percents reported to date and might suggest that 
there was an outbreak of hMPV during the study period. Phyloganetic analysis of 34 
(14%) positive hMPV amplified RNA of the N-gene showed that two serotypes of 
hMPV A lineage circulated in Southern Palestine.  Indeed, one of the serotypes was 
not the same as that reported for the reference strains.  Of the sequenced samples, 
43% belonged to a novel clade of the lineage A.  Upon determining the homology of 
the newly discovered clade, 95% homology was observed.  Having this 5% 
difference from the 377 base pair sequences allowed to hypothesize that we are 
dealing with a new clade of the A lineage.  
This study is the first to report and describe the epidemiology of hMPV in Southern 
Palestine. Moreover; it identified the genetic lineages and clades that circulated in 
Southern Palestine. The discovery of hMPV and its incorporation to routine 
diagnostic procedures has allowed us to identify the cause of a significant number of 
respiratory tract infections (31.8%) during the study period. 
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 1 
1. INTRODUCTION 
1.1 Background  
Respiratory tract infections (RTI) are one of the main causes of morbidity 
and mortality worldwide (1).  RTI ranked second as the leading cause of death in 
children less than 5 years of age, regardless of the country they live in (2).  When 
age and gender are not taken into consideration, severe respiratory tract infections 
(pneumonia, influenza, and influenza-like illnesses) are considered to be the most 
common sicknesses; ranked as the sixth mortal illnesses in the United States, with 
greater than 45,000 deaths reported annually (3). 
  Reports from the US have showed that $14.6 billion is the estimated cost 
for 4 million patients presenting with severe respiratory tract infections requiring 
on-sight medical care from  which 500,000 cases require hospital intervention (4). 
In the Netherlands, as high as 5,445 RTI per 10,000 persons are reported annually 
(5). One major issue about severe respiratory tract infections is that, although 
clinical symptoms can easily be identified, the original cause of the disease 
remains often unidentified.   Less than 50% of community-acquired pneumonia 
cases can be microbiologically diagnosed (6, 7). In children, bronchiolitis and 
lower respiratory tract infractions (LRTI) are mainly due to respiratory syncytial 
virus (RSV).  However, parainfluenza viruses, and influenza viruses have also 
been reported to cause RTI’s (8, 9).  In most cases, LRTI infections are said to be 
caused by a virus (10); nevertheless, and even with the presence of state of the art 
genomic amplification, the virus can be identified in 40% of the cases (11).  
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 One of the pathogens implicated in causing RTI, has been recently 
identified as the Human Metapneumovirus (hMPV).  Human Metapneumovirus 
(hMPV) a member of the Paramyxovirdidae, subfamily pneumovirinae is a 
pleomorphic enveloped virus with an average diameter of approximately 200 nm 
(range, 150-1000 nm). hMPV genome is single-stranded RNA (13 kb) with 
negative polarity and based on sequence analysis the virus has two genetic 
lineages A and B.  Respiratory Syncycial Virus (RSV), another member of the 
Paramyxovirdidae family has similar genetic organization and clinically produces 
similar symptoms in infected patients. 
It  is  closely related to the avian metapneumovirus (APVs) and has existed 
in the human population for at least 50 years (12). In the year 2001, Van Den 
Hoogen was the first to identify this virus (12). The virus was first isolated from 
children with acute respiratory tract diseases. It would be worth noting that, the 
hMPV was also identified in other age groups (13-16). 
Van Den Hoogen evaluated nasopharyngeal aspirates (NPA), from patient 
samples stored for over 20 years where hMPV was isolated and characterized 
from 28 samples.  Since this initial discovery, many reports have confirmed the 
prevalence of hMPV in the world Netherlands (12), Canada (17), France (18), 
Australia (19), Denmark (20), Argentina (21), Tunisia (22),  Italy (23), USA (14), 
Japan (24), and Israel (25, 26), and identified hMPV as an important respiratory 
pathogen in children. 
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In 2-25% of the cases, children who were reported to present with acute 
bronchiolitis have shown the presence of hMPV in their nasopharyngeal samples. 
Human respiratory syncytial virus (hRSV) infection has a similar clinical 
syndrome, but with some cases characterized by respiratory tract infection and 
others by severe bronchiolitis and pneumonia. Out of a large number of reports 
few reports have shown that hMPV infection is associated with asthma 
exacerbation (18, 27, 28) and a single report indicated this association to be less 
strong than that of asthma and rhinovirus infection (29). There are several ways 
for the hMPV to be transmitted from one individual to another: by direct contact 
with respiratory secretions, by contact via large aerosolized droplet, and by 
contact via handled surfaces.  
1.2 The classification of hMPV 
The human Metapneumovirus (hMPV) member of the Paramyxovirdidae, 
subfamily pneumovirinae is a pleomorphic virus. It is an enveloped virus with an 
average diameter of approximately 200nm (range, 150-1000 nm) (Figure 1). 
hMPV genome is single-stranded RNA (13 kb) with negative polarity.  hMPV 
have a helical nucleocapsid, and has glycoprotein surface with projections. 
 
Figure 1: hMPV picture taken by Electronic Microscope 
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The Metapneumovirus genome encodes eight distinct transcription units in 
a linear array, with each unit separated by a short segment of untranscribed 
sequence. The nucleotide sequence analysis of the virus showed that the gene 
order from 3` end to 5` end as follows: 3`- N-P-M-F-M2-SH-G-L- 5` (Figure 2).  
 
Figure 2: Genomic structures of human Metapneumovirus (hMPV) 
1.3 hMPV proteins:  
a. Nucleocapsid binding protein (N): The N protein responsible for the helical 
structure of the RNA through its direct association with the virus RNA genome 
forms an integral part of the nucleocapsid complex of the virion and is an essential 
element of the polymerase complex.  
 The N gene encoding region is 1185 bases in length, the gene start 
sequences contains (GGGACAAG/AU) motif that is identical to the gene start 
signal characterized for the Avian pneumovirus  (APV) subgroup A, B, and C. 
(30-33). The putative gene end signal for the hMPV N gene (AGUAAUUA6), is 
identical to the one characterized for the APV-C (30).   
 Deletion mutant analysis expressed in cells suggests that a large segment 
of N protein is required for interacting with the P protein (34). Barr and Easton 
(35) demonstrated that the amino-terminal half of the pneumonia virus of mice 
(PVM) N protein was unable to bind to immobilized P protein while the carboxy-
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terminal half of the N protein bound with only 17.6% of the affinity seen with the 
full-length protein, results suggesting that the complete N protein is important for 
this interaction.  
 b. Phosphoprotein (P): One of the essential components in the replication and 
transcription complexes of pneumoviruses is the P protein (31, 36, 37). The 
carboxy terminus of the P protein contains most of the elements necessary to bind 
to the N protein (28, 34, 38, 39); analysis of the P protein has shown that when 
using different start codons, the P-protein genes of the Pneumovirinae encode 
several different proteins.  
Moreover, and as demonstrated by Villanueva et al. (40), at specific serine 
residues (41), the P protein is phosphorylated and most of the phosphorylation, 
occurring at residues 116, 117, 119, and 232, is not essential for transcription or 
replication.  
c. Large polymerase protein (L): Contain 2000 amino acids (37, 42). The L 
protein is thought to be responsible for mRNA methylation and capping, as well as 
one major component of the viral RNA-dependent RNA polymerase complex, 
responsible for the synthesis of all viral RNA, including mRNA, replicative 
intermediates, and the progeny RNA genomes.  
d. M2 proteins:  the mRNA, encoded by the M2 gene, contains two overlapping 
open reading frames (ORFs) M2-1and M2-2 (37, 43, 44): M2-1 being the 
transcription elongation factor and M2-2, the RNA synthesis regulatory factor. 
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The first open reading frame, initiated by the 5'-proximal AUG initiation 
codon, encodes the M2-1 protein, which is involved in virus RNA synthesis while 
the expression of the M2-2 open reading frame resulted in the inhibition of virus 
gene expression from synthetic genomes. This protein is believed to switch the 
virus from replicative to assembly mode, prior to the release of the virion (43). 
e. Matrix protein (M): The M protein, including a carboxy-terminal hydrophobic 
domain, is linked with the inner face of the lipid membrane of infected target cells 
(45). Analysis show that M proteins of nonsegmented minus-strand viruses 
function by promoting the association of the nucleocapsid complex with the 
nascent envelope (46), and rendering the nucleocapsid transcriptionally inactive 
before packaging. 
 f. Major attachment glycoprotein (G): Observations showed that G-specific 
polyclonal antibody blocked the absorption of the virus to the surface of target 
cells (47), therefore leading to its identification as a viral attachment protein. The 
role of pneumovirus G proteins, heavily glycosylated with both N- and O-
glycosylated sites, have not been completely clarified. If the extra-cellular domain 
of the G protein witnesses a broad glycosylation, its antigenicity will then be 
reduced by shielding the virus protein with host-specified sugars. On the other 
hand, if glycosylation sites are to be partially utilized, then antigenic heterogeneity 
might occur, representing a source of diversity within a genetically homogenous 
virus population. 
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g. Fusion protein (F): The F protein is considered as being an inactive precursor 
(F0) accumulating in the rough endoplasmic reticulum (ER) into a homo-oligomer 
forming a structure seemingly representing a single virion spike (48). Then the F0 
is sub-divided by cellular protease into two subunits, F1 and F2 (49, 50). The 
pneumovirus F proteins have several identical structures as other members of the 
paramyxoviridae family, although they only show limited amino acid sequence. 
h. Small hydrophobic proteins (SH): The SH proteins of pneumoviruses are 
small integral membrane proteins, of the size of 183 amino acids (51). Several 
analysis of hMPV mutants, lacking the SH and/or G genes, state that SH protein 
in not necessary for attachment, infectivity, or virion assembly.  
1.4 Current Model for Transcription 
Details of the present model for transcription and replication of the 
pneumovirus genomes are similar to those of the non-segmented negative-sense 
RNA viruses. The virus genome contains a single polymerase entry site, labeled 
the leader or promoter sequence, at the 3' end of the RNA. At the beginning of 
each transcribed gene is a conserved transcriptional start sequence which is 
initiated by the polymerase complex. The latter then travels along the genome 
until reaching a conserved signal that marks the point at which transcription ends. 
At some point during the transcription process, the embryonic mRNA is 
methylated to produce a cap structure that ensures translation on host cell 
ribosomes; there are no reports directly addressing this process. The end of 
transcription among the pneumoviruses is marked by a signal containing a short 
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run of U residues, pointing the position at which the polyadenylated tail is added 
to the mRNA. At the completion phase of the polyadenylation process, the mRNA 
is released for translation on either free or membrane-bound ribosomes, depending 
on the nature of the protein product. At this point, only a proportion of the active 
polymerase molecules progress along the genome, with estimates suggesting that 
approximately 50% of the polymerase molecules are able to continue. Dissociated 
polymerases can reinitiate transcription at the first gene by translocation to the 3'-
terminal leader region. Without transcription, the remaining polymerases traverse 
the genome until they encounter the conserved transcriptional start sequence of the 
second gene. At the end of this gene, the remaining polymerases repeat the 
dissociation-versus-continuation process. The result is that genes proximal to the 
3' leader region are represented in mRNA more abundantly than are those closer to 
the 5' end in a gradient of transcription (52). The inter-genic regions of the 
pneumoviruses vary in length and tolerate mutation and insertion of additional 
nucleotides (37, 53, 54). 
 Based on the RSV model, the M2-1 protein has proved its necessity in the 
production of full-length virus mRNA (48, 55, 56). The anti-termination activity 
during transcription allows the viral polymerase to remain associated with the 
template, thus increasing the production of full-length mRNA and bettering the 
production of products of genes that are distal to the 3' leader region. Although 
they vary in their sensitivity to the presence of the M2-1 protein and in their 
ability to terminate transcription, the eight RSV gene junctions all direct the 
production of more read through mRNA in the presence of M2-1 protein (57). 
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 Nevertheless, the genome structure of hRSV contains an exception to the 
above explained process. At the 68 nucleotides downstream of the transcriptional 
start sequence for the L gene is the transcriptional stop signal for the M2 gene(58). 
Therefore, a large proportion of the mRNA initiated at the L-gene start sequence 
terminates at the M2 transcriptional stop sequence (58).  
Elements within inter-genic regions play a major role in the regulation of 
transcription. In fact there are important sequence diversity in length in the inter-
genic regions of the Pneumovirinae, vary from 2 to 56 nucleotides. The 
transcriptional start sequences are thought to be 10 nucleotides in length, and the 
consensus sequences, while conserved, are slightly different for each pneumovirus 
(59). The RSV or APV transcriptional start signals are less variable than that of 
the PVM since they are absolutely conserved with the exception of the L gene 
(60).  
The transcriptional stop signals of hRSV consist of a conserved 
pentanucleotide sequence together with a 1- to 4-nucleotide A U-rich region and a 
4- to 7-nucleotide poly (U) tract. Saturation mutagenesis of the hRSV gene 
transcriptional start sequences showed that residues 1, 3, 6, 7, and 9 were critical 
in directing transcription initiation, although there was some variability in 
efficiency, particularly with the NS1 and NS2 gene start sequences, which were 
approximately 40% less efficient than the others(59, 61). 
As a result from the deletion of a transcriptional stop signal from an 
upstream gene a transcriptional read-through to the next gene without termination 
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was made. After analyzing the hRSV M-gene transcriptional stop sequence, 
Harmon et al. (62) determined that the integrity of the pentanucleotide and AU-
rich regions are very important for efficient termination. The residue following the 
poly (U) tract might also be important for efficient transcription termination (63). 
Nevertheless, there wasn’t any significant difference in transcriptional 
activity or efficiency with different sized RSV intergenic sequence (61). An 
analysis of Bukreyev et al. (64) showed the recovery of a recombinant hRSV 
containing an intergenic region of 160 nucleotides, which had little effect on 
sequential transcription.  
1.5 Current Model for Genome Replication 
The current model, based on that determined for other nonsegmented 
negative-sense RNA viruses, proposes that the nucleocapsid complex is the 
functional unit for both replication and transcription and that the L, N, and P 
proteins are involved in both processes.  There is in fact a big similarity between 
the transcription and replication promoters of hRSV. In the replicative mode, the 
polymerase binds to the 3' end of the genome RNA and initiates RNA synthesis de 
novo. Once begun, the polymerase produces and antigenome at the end of the 
template. The polymerase complex then uses the antigenome as a template, 
binding to and initiating RNA synthesis at the 3' end of the antigenome RNA. In 
the genome sense RNA, the trailer region contains the anti-sense copy of the 
sequence necessary for initiating replication to produce more genome RNA from 
the antigenome.  
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So far, no study has clearly identified how the polymerase complex alters 
its activity and switches from the transcription to the replication mode. Fearns et 
al. (65) showed that hRSV replication was stimulated by increased expression of 
the N protein.  Nevertheless, conflicting data suggest that high levels of N protein 
may also stimulate transcription (66). 
The 3' and 5' termini of the pneumovirus genome contain the sequences 
that direct replication. Reverse genetics studies showed that the 3'-terminal 44-
nucleotide leader region and the 5'-terminal 40 nucleotides of the trailer region of 
hRSV were necessary for replication, encapsidation, and assembly (67). The 
immediate termini of the pneumovirus genomes have complementary sequences, 
as has been described for other negative-sense RNA viruses (37). The trailer 
sequences are more efficient than the leader sequences at directing replication, as 
would be expected from their role in replication and the requirement for the leader 
region to direct both replication and transcription (68).  
Analysis of the leader and trailer sequences suggested that nucleotide 
positions 1, 2, 3, 5, 6, and 7 were particularly important for replication, while 
position 4 was found to be tolerant of alteration. Using synthetic chimeric 
minigenomes with terminal sequences from both APV and RSV in virus infected 
cells, Marriott et al. (69) showed that paired termini from the same virus were 
required for replication to occur. It is not clear whether the critical step is 
replication or encapsidation, but the data suggest that an association between the 
leader and trailer is necessary for productive infection (69).  
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1.6 Packaging and Assembly 
Reverse genetics experiments suggest that the accumulation of the M 
protein may be a component of the trigger to initiate the assembly of virions. It is 
anticipated that the nucleocapsid complex/M-protein structure associates with the 
internal tails of the major glycoproteins that are inserted into the membrane of the 
infected cell after processing through the Golgi complex. In parallel with studies 
performed with other viruses, a progressive series of interactions between the 
glycoproteins and the M protein, which acts as a bridge with the nucleocapsids, 
results in the progeny virions budding from the surface of the cell in the form of 
filament structures. In polarized cells, such as those of the respiratory tract, hRSV 
buds from the apical surface and is shed into the airways, from which it can be 
transmitted to new hosts(70). 
1.7 Taxonomy    
Genetically speaking, the closest relative to the hMPV, member of the 
Paramoxivirdidae, subfamily pneumovirinae, is the avian pneumovirus type C 
(See below). hMPV is the only known human pathogen of the genus 
Metapneumovirus. However, clinically, it is quite similar to the Respiratory 
syncytial virus (RSV), a common respiratory pathogen classified in the family 
Paramoxivirdidae, subfamily Pneumovirinae.  Following is the diagram detailing 
the taxonomy of this family. 
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Order: Mononegavirales 
           Family: Paramyxovirdidae 
                   Subfamily: Paramyovirinae  
                              Genus: Respirovirus 
                                         Species: Human parainfluenza type 1 and 3 
                              Genus: Rubulavirus 
                                         Species: Human parainfluenza type 2 and 4 
                              Genus: Morbillivirus 
                                         Species: Measles virus 
                              Genus: Henipavirus 
                                         Species: Hendra virus. Nipah virus 
                   Subfamily: Pneumovirinae 
                              Genus: Pneumovirus 
                                         Species: Respiratory syncytial virus  
                                                 Subgroup: A and B 
                              Genus: Metapneumovirus 
                                         Species: Human Metapneumovirus 
                                                 Subgroup: 1 and 2 
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1.8 hMPV Lineages:  
Several sequence analysis of hMPV isolates showed that there are two 
main genetic lineges (A and B) each representing two sub lineages, A1, A2, B1 
and B2 (Figure 3). However lineage A2 appears to have two clusters, tentatively 
named A2a and A2b. This division of subgroup A2 is supported by bootstrap 
values (94% and 98%), considered high when compared to those found for widely 
accepted partition of A1 and A2. 
In Germany, a new variant of hMPV isolated from a 6.5 years old child 
was reported by Schildgen et al, where alignment of 302 nucleotide human 
metapneumovirus (hMPV) sequences amplified from brain and lung tissues of the 
patient and from the supernatant of infected Vero cell culture and the sequence of 
the hMPV strain NLD00-1 was used as a prototype sequence.  
The two viral genotypes have a similar genomic organization. The major 
differences between genotypes 1 and 2 are nucleotide polymorphisms and the G 
and SH protein contains the highest concentration of these polymorphisms. The G 
gene of hMPV shows an important strain-to-strain variability, resulting in 
significant amino acid variability, mostly observed in the putative extra-cellular 
domain of the protein. 
The amino acid identity of the expected determined proteins between the 
two strains is 96 % (N protein), 85% (p protein), 97% (M protein), 95% (F 
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protein), 96% (M2-1 protein), 89% (M2-2 protein), 59% (SH protein), 37% (G 
protein), and 94% (L protein). 
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Figure 3: Phylogenetic analysis of hMPV 2 lineages (A and B) and 4 serotypes (A1, A2, B1, B2)  A1-(AF371337.2) 
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1.9 Epidemiology 
hMPV (be consistent, either hMPV or HMPV) has been detected in patient 
samples from the following countries: Netherlands (12), Canada (17), France (18), 
Australia (19), Denmark (20), Argentina (21), Tunisia (22),  Italy (23), USA (14), 
Japan (24), and Israel (25, 26).  
hMPV was mostly found to circulate in the late winter and spring, as well 
as in the peak of activity at any given location, often coinciding with or following 
the peak of the RSV activity. 
It would be worth noting that hMPV is also detectable at lower levels 
during late spring, summer and fall. Its phylogenetic analysis of strains reveals 
that the epidemiology of this local phenomenon is complex and dynamic. Strains 
of hMPV differ from one community to another, and strains identified in one 
location may be quite similar or different from other identified in other locations 
in different years. 
RSV and hMPV has similar epidemiological features, where subgroups of 
the virus co-circulate each year and the strains vary from area to another area and 
from different years as well. Moreover switching from one strain to another strain 
of same virus is observed.  
 
 
 18 
 1.10 Pathogenesis 
Ciliated respiratory epithelial cells changes and increased inflammatory 
cell infiltrates, predominantly mononuclear cells, in the lung interstitium was 
observed in experimental animals infected with hMPV. Moreover, hMPV virus 
uses specific strategies to overcome host defenses, similar to RSV, this virus can 
persist for several weeks in the lungs, despite an established immune response. 
Furthermore, hMPV infection causes increased myofibroblast thickening adjacent 
to the airway epithelium and staining of cellular debris. 
Airway epithelium are the first infected cells with hMPV, that results in 
cell degeneration and/ or necrosis, with ciliacytophthoria and round, red 
cytoplasmic inclusions on a background of haemosiderinladen macrophages, 
abundant neutrophils and prominent mucus. 
Lung biopsies performed at least one month after a positive hMPV nasal 
assay, have shown that later stages of the disease caused by hMPV include 
expansion of peribronchiolar lymphoid tissue, squamous metaplasia, haemosiderin 
and accumulation of intra-alveolar foamy macrophages. These features indicate 
chronic/ healing airway obstruction and impairment of the mucociliary escalator, 
and correlate well with the bronchiolitis and wheezing noted clinically in patients 
with hMPV infection.  
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a. Clinical manifestation of the hMPV infection 
hMPV is responsible of a substantial proportion of LRTI in infants and 
young children and is second to RSV as a cause of bronchiolitis in early 
childhood. The incidence estimated range from 5 to 15% in most studies.   
In most cases, an association between the LRTI and the hMPV in infants 
and young children requires clinical intervention. Severe cases of LRTI require 
intensive care, and one case required of extracorporeal membrane oxygenation.  
Several signs and symptoms may help diagnose the hMPV infection; these 
range from rhinopharyngitis to bronchitis and pneumonia - some patients may 
even be admitted to intensive care units. A summary of the clinical data for a 
group of children seen in an emergency department for acute respiratory infection, 
grouped according to virus diagnosis is shown in (Table 1).  Signs and symptoms 
caused by hMPV resemble those of RSV infection (bronchiolitis, asthma 
exacerbation and pneumonia) and sometimes those of influenza (fever and upper 
respiratory tract infection). The clinical presentation of hMPV infection have also 
been associated with febrile seizures, rash, diarrhea, enlarged liver, and altered 
liver function test results (Table 2). 
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Characteristics 
 
hMPV positive 
(n=41) 
 
RSV positive      
(n=117) 
 
Influenza positive 
(n=209) 
Clinical presentation    
Common cold, no.(%) 3 (7.3) 20 (17.1) 43  (20.6) 
Pharyngitis, no (%) 11 (26.8) 20 (17.1) 73 (34.9) 
Acute otitis media no (%) 5 (12.2) 10 (8.5) 34 (16.3) 
Croup, no (%) 3 (7.3) 4 (3.4) 7 (3.3) 
Acute bronchitis no (%) 4 (9.8) 15 (12.8) 20 (9.6) 
Wheezing, no (%) 10 (24.4) a 30 (25.7)a 14 (6.7) 
Pneumonia, no (%) 5 (12.2) 18 (15.4) 18 (8.6) 
Clinical outcome    
Hospitalization, no (%) 2 (4.8) 16 (13.7) 11 (5.3) 
School absence Median days 
(range) 
10 (3-15) 10  (3-12) 12 (5-15) 
Table 1. Clinical characteristics and outcomes among children seen for acute respiratory infection 
in an emergency department, grouped by virus RNA detection (71). 
 21 
 
 
Characteristics 
 
hMPV positive/Total 
(%) 
 
RSV positive /Total 
(%) 
 
Influenza positive /Total 
(%) 
Influenza-like illness in family contact 10/19 (52.6) 7/29 (24.1) 19/24 (79.1) 
Febrile seizure 5/32 (15.6) 1/32 (3.1) 3/32 (9.4) 
Congested pharynx 12/32 (37.5) 11/32 (34.4) 11/32 (34.4) 
Rash 4/32 (12.5) 1/32 (3.1) 4/32 (12.5) 
Enlarged liver 2/32 (6.3) 0/32 (0.0) 4/32 (12.5) 
Otitis media 4/32 (12.5) 0/32 (0.0) 0/32 (0.0) 
Diarrhoea 2/32 (6.3) 1/32 (3.1) 3/32 (9.4) 
Crepitations 18/32 (56.3) 14/32 (43.8) 3/32 (9.4) 
Wheezing 9/32 (28.1) 12/32 (37.5) 2/32 (6.3) 
Asthma exacerbation 6/32 (18.8) 2/32 (6.3) 2/32 (6.3) 
Acute bronchiolitis 3/32 (9.4) 10/32 (31.3) 0/32 (0.0) 
Pneumonia 12/32 (37.5) 5/32 (15.6) 1/32 (3.1) 
Abnormal chest X-ray 17/25 (68.0) 11/18 (61.1) 1/17(5.9) 
Lymphopenia (<1.5 * 10 /L) 9/31 (29) 2/27 (7.4) 12/29 (41.4) 
Neutropenia (ANC <1* 10/L) 2/31 (6.5) 0/27 (0.0) 4/29 (13.8) 
Elevated transaminase 2/15 (13.3) 0/5 (0.0) 3/11 (27.3) 
Table 2 Characteristics of 32 children admitted with human Metapneumovirus infection compared 
to age-matched controls with respiratory syncytial virus or influenza A infection (71). 
hMPV was found to cause severe symptoms in infants and patients with 
chronic illnesses; one death was reported in an immuno-suppressed patient (72). 
Laboratory analysis reported 32 hospitalized children under the age of 18 months, 
of which 29% had lymphopenia and 6% had elevated transaminases (28).  In 
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another group of 10 hospitalized children, normal White Blood Counts and 
elevated C– reactive protein levels were reported (27). 
In the Netherlands most of the people over 5 years of age have been 
exposed to the hMPV (12), and in southern part of Israel, over 50% of children 
that are less than 2 years of age  have been infected with hMPV (25). 
The infection of a patient by both the hMPV and other respiratory viruses 
may contribute to severe illnesses. Moreover, the co-infection with hMPV and 
RSV has been hypothesized to cause severe disease, often-requiring intensive care 
admission, and ventilatory support (73).   
1.11 Diagnosis: 
  Amongst the available diagnostic tests for hMPV are: the viral culture, 
immunofluorescence assays (IFA), and polymerase chain reaction (PCR).  Other 
tests can be used to determine if the patient might have viral infections includes 
Complete Blood Count and C-Reactive Protein. 
a. Viral culture: 
The hMPV virus only grows slowly in tertiary monkey kidney cells 
supplemented by trypsin for propagation as described by van Den Hoogen. It is 
difficult to isolate it since it does not grow readily in tissue culture cells routinely 
used in the viral diagnostic laboratory.  
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Following is a small brief of how the process functions: The virus isolates 
replicated slowly in tertiary monkey kidney (tMK) cells, very poorly in Vero cells 
and human respiratory epithelial cell line (A549 cells), and cannot be propagated 
in Madin Darby canine kidney (MDCK) cells or chicken embryo fibroblasts 
(CEF). The virus isolates causes a cytopathic effect on cells and are virtually 
indistinguishable from those caused by hRSV, with characteristic syncytia 
formation followed by rapid internal disruption of the cells and subsequent 
detachment from the culture plate. This cytopathic effect is visible at day’s 10−14 
post inoculation, slightly later than the cytopathic effects induced by hRSV-
containing specimens. 
b. Immunofluorescence assays (IFA)  
 IFA is performed using Vero cells infected with the hMPV reference 
strain are mixed with uninfected Vero cells at a ratio of 70% and 30%, 
respectively. The cells are then spotted on acetone-cleaned glass slides and left to 
dry at room temperature. The cells on each slide are then fixed with ice-cold 
acetone and stored at –70°C until used. Patient's sera are serially diluted in 
phosphate-buffered saline and incubated with either hMPV-infected or uninfected 
(negative control) fixed Vero cells for 45 min at 37°C. The cells are then washed 
three times with phosphate-buffered saline and incubated with fluorescein 
isothiocyanate-conjugated AffiniPure goat anti-human immunoglobulin G, Fc 
fragment specific (Jackson ImmunoResearch Laboratories, Inc.) for 35 min at 
37°C in a humidified box. Cells are then washed and dried, and mounting fluid 
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was added. A inverted fluorescent microscope is used to visualize the samples. 
Patient samples with a titer greater than 1:32 are considered positive for hMPV 
antibodies as described by van den Hoogen et al.  
 
c. Molecular Diagnosis by One- step Reverse transcriptase – Polymerase 
chain reaction ( RT-PCR ) 
Nowadays, RT-PCR is the mostly followed method to detect hMPV. 
Briefly, cDNA is synthesized from total RNA extracted from each nasopharyngeal 
swab sample. A forward primer and a reverse primer are used to detect the viral 
protein gene needed for the study. RT-PCR is to be performed on extracted RNA. 
Amplicons were visualized by ethidium bromide staining following 
electrophoresis on a 2% agarose gel.  
The N and L genes codes for two internal viral proteins particularly 
suitable and highly sensitive for the detection of hMPV strains of both genotypes. 
Comparative studies for the sensitivity of real-time RT-PCR assay to amplify the 
viral nucleoprotein (N), Matrix (M), Fusion (F), Phosphoprotein (P), and 
polymerase (L) genes, showed that. 
The accuracy and timing of the diagnosis is a major element in the 
appropriate treatment of patients with respiratory illnesses. An early diagnosis of 
viral infections can reduce the inappropriate use of antibiotics and provide the 
option of using antiviral therapy. However, if suspected, bacterial infections 
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should be considered and appropriately treated because certain bacterial infections 
can produce symptoms similar to viruses. In addition, bacterial infections can 
occur as a complication of viral infections.  
For a more serious treatment, hMPV surveillance information and 
diagnostic testing are a must. And since symptoms from illness caused by other 
pathogens can overlap considerably with hMPV, the accuracy of clinical diagnosis 
of hMPV on the basis of symptoms alone is limited. 
1.12 Treatment 
The medical care treatment is supportive: maintain hydration and provide 
supplemental Oxygen if necessary. In patients with respiratory failure, mechanical 
ventilation is necessary. It is clear that there is a need for agents that can prevent 
or ameliorate infections caused by the hMPV virus. 
a. Ribavirin is a compound with known broad-spectrum antiviral activity, 
suggested for the treatment of hMPV infections. However clinical use of ribavirin 
is contagious, because it is a potential teratogen, and thus is a potential health 
hazard; it is also an expensive medicine.  Despite these problems, ribavirin has 
shown to be effective in limiting the disease and mortality in immunosuppressed 
people infected with hRSV provided that treatment is started early.  
b. NMSO3, a sulfated sialyl lipid that has a potent antiviral activity 
against hRSV in tissue culture cells, has shown antiviral activity against hMPV 
 26 
too. Clinical trials of anti-human Metapneumovirus monoclonal antibodies for 
prevention of hMPV infections in high risk infants are being investigated. 
1.13 Vaccination against hMPV 
Several promising vaccine candidates have been tested in animal models. 
A live recombinant human parainfluenza virus that contains the hMPV F gene has 
been shown to induce hMPV – specific antibodies and to protect experimental 
animals from hMPV challenge. These animals produced antibodies specific for 
the hMPV F protein.  
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2. Materials and Methods 
2.1 Study Location 
This study was performed at the Caritas Baby Hospital (CBH).  CBH is 
located in the Southern part of Palestine. CBH is a non-profit charitable hospital 
that serves the children of Bethlehem and the surrounding villages and cities. The 
primary aim of this institution is to provide services mainly for low-income 
families. The hospital has capacity for 89 beds and incubators located in three 
wards; premature ward, and two wards for babies and toddlers. 
 
2.2 Patient Demographics and study period 
Patients (N=790) admitted to CBH with acute respiratory tract infections 
as the main cause of illness between the period November 1st 2005 and October 
11th 2006 were enrolled in this study. The majority of the patients were residents 
of Bethlehem district (63.2%), followed by Hebron (34.3 %), Jerusalem (1.5%), 
Jericho (0.63%), Ramallah (0.25%) and Nablus (0.13%). The patients' age ranged 
from one day old new born to 13 years old children.  Stratifying the patients by 
age group, most of patients where less than two years old (92.66%) (Table 3) and 
the male to female ratio was 493 (62.4%) to 297 (37.6%), respectively.   
 28 
 
Age Group Number of 
Children 
Infected / 
Percent 
< 6 Months 475 60.1% 
0.5-1 Y 189 23.9% 
1-1.5 Y 68 8.61% 
1.5-2 Y 24 3.04% 
2-2.5Y 15 1.90% 
2.5-3 Y 11 1.39% 
3-3.5 Y 1 0.13% 
3.5-4 Y 1 0.13% 
4-4.5 Y 2 0.25% 
4.5-5 Y 1 0.13% 
5-5.5 Y 1 0.13% 
5.5-6 Y 0 0.00% 
6-6.5 Y 1 0.13% 
>7 Y 1 0.13% 
Total 790 100% 
 
Table 3: Age distribution of patients infected with hMPV 
 
2.3. Patients Samples Collection and Preparation 
 
a. Collection of nasopharyngeal aspirates: 
 Nasopharyngeal aspirates (NPA), the gold standard patient specimens for 
the diagnosis of respiratory tract infections, were collected according to the recent 
European Respiratory Society guidelines.  Health care providers were educated on 
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the proper methods of specimen collection, storage, and transport.  Briefly, a 
sterile soft polyethylene #8 French feeding suction tube was attached to a 
disposable aspiration trap. Using the tube, the distance from patient’s nostril to the 
ear was measured; the distance was marked on the tube using the thumb and 
forefinger. The tube was then gently inserted into the nostril until using half the 
distance the thumb and forefinger touch the patient’s nose.  Intermittent suction 
was applied; the tube was slowly removed from the nasopharynx. The end of the 
tube was placed in a vial containing sterile saline and the contents were aspirated 
into the trap (don’t leave the specimen in the tubing). The trap was closed tightly 
with the cover making it leak proof.  
The trap was labeled with patient’s information, and send to the laboratory within 
30 minutes. If the specimen was not analyzed immediately, it was kept 
refrigerated at 2-8 oC. 
 
b. DFA Slide Preparation: 
Patient NPA samples were vortexed for 30 seconds to loosen the mucus 
and release the trapped cells. The samples were then centrifuged at 300 x g for 10 
minutes followed by removing the supernatant.  PBS 5 ml at (4 oC) was then 
added to the pellet to wash and loosen the cell pellet by gentle mixing using a 
clean disposable pipette.  The samples were then centrifuged at 300 x g for 10 
minutes followed by decanting the supernatant into the waste container. This step 
was repeated one more time to ensure that the cell pellete is clean and the cells are 
loose.  The pellet was then resuspended in 0.2-0.5 ml with cold PBS.  The cells 
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were then spotted on acetone cleaned and air dried 8 well slides. The cells were 
then fixed with ice cold acetone for 10 minutes.  An aliquot of the patients' cells 
were kept in a sterile eppendorf tube and stored at -25 oC.  
 
2.4 DFA Staining: 
 FITC labeled antibodies against each of the viruses (Influenza A and B, 
RSV A and B, Parainfluenza viruses 1, 2, 3, and Adenovirus) were added to the 
appropriate well and incubated at 37oC for 30 minutes. The slides were then 
washed for 45 sec with 0.5% Tween 20 / PBS, followed by washing with distilled 
water for 15 seconds. The slides were then dried on a slide warmer. The slides 
were then mounted with mounting oil, and examined for the presence of 
fluorescence using a Hund H 600 fluorescent microscope at 20X and confirmed at 
40 X.  Each slide was screened for the presence of ciliated cells as an indication 
that the sample was collected properly. 
 
2.5 Identification of Positive cells 
A positive result was indicated by the presence of two or more intact cells 
exhibiting specific fluorescence. The presence of only one single positive cell was 
considered to be positive after the evaluation of an expert. A negative result was 
indicated by the absence of fluorescence in a minimum of 20 ciliated epithelial 
cells. Samples containing fewer than 20 ciliated epithelial cells were considered 
inadequate. The staining pattern varied with the infecting virus and the stage of 
growth. Fluorescent staining pattern was nuclear and/or cytoplasmic and often 
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punctate; it was bright apple green for FITC-labeled antibodies and reddish gold 
for rhodamine-labeled antibodies. 
 
2.6 Virus and Bacterial stocks: 
hMPV reference strain virus 200026583 (CAN-83) passage 3. For 
specificity testing, the RT-PCR assay did not cross react with influenza virus A, 
influenza virus B, RSV, parainfluenza viruses 1, 2, 3, and adenovirus.  ATCC 
bacterial strains where used to measure the specificity of the RT-PCR assay.  The 
strains used were Haemophilus influenzae (ATCC 49766), Escherichia coli 
(ATCC 25922), Staphylococcus aureus (ATCC 25923), Pseudomonas aeruginosa 
(ATCC 27853), Streptococcus pyogens (ATCC 19615), Streptococcus pneumonia 
(ATCC 49619), and Moraxella catarrhalis (ATCC 25239) and one clinical 
bacterial isolate (Klebsiella pneumoniae). 
 
2.7 RT-PCR sensitivity. 
The sensitivity and specificity of the assay developed in this lab was 
challenged with Quality Control for Molecular Diagnostics (QCMD) external 
quality control 2006 batch.  Twelve QCMD RNA samples were analyzed with the 
in house hMPV RT-PCR assay.   
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2.8 Molecular Diagnosis 
a. Primers design: 
Two sets of primers published by Maertzdorf et al (74) were modified and 
used to detect all hMPV strains from all known genetic lineages. The primers 
targeted the most conserved sequence within the nucleoprotein gene (N gene) 
(Table 4). 
 
 
Forward primer Reverse primer 
NL-N (73) CAT ATA AGC ATG CTA TAT TAA AAG AGT CTC CCT ATT TCT GCA GCA TAT TTG TAA TCA G 
NL- N- CBH CAT AYA AGC  ATG CTA TAT TAA AAG AGT CTC CCT ATT TCT GCA GCA TAT TTG TAA TCA G 
   
ALT-N (73) CAA CAA CAT AAT GCT AGG ACA TGT ATC CCG AGA ACA ACA CTA GCA AAG TTG 
ALT- N-CBH YAA CAA YAT AAT GYT AGG ACA TGT ATC CCG AGA ACA ACA CTW GCA AAG TTG 
 
Table 4: Alignment of sequences of primers for the NL-N and ALT-N assays with the target 
sequences of the hMPV. Residue Y represents a C or a T, and W represents A or T  
 
A 162 bp fragment was amplified with NL-N- Forward, and NL-N-
Reverse; while a 176 bp fragment was amplified after the utilization of the ALT-
N-Forward, and ALT-N-Reverse.  We utilized the NL-N set of primers for hMPV 
screening, since this set of primers gave us consistent, sensitive and reproducible 
results.  Moreover, for phylogenetic analysis, we established an RT-PCR assay 
using the NL-N-Forward and ALT-reverse which amplified a 1019 bp fragment 
that was used for sequencing. 
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b. Contamination control: 
All extraction procedures were performed inside a Biological Safety Hood 
-2.  Before each extraction procedure, the hood was cleaned with 0.5% bleach, 
followed by 70% alcohol.  The same procedure was performed after each 
extraction procedure. White absorbent paper was then added on the hood surface. 
All extraction racks and pipettes were also cleaned with 0.5% bleach, followed by 
70% alcohol before and after each usage. All these extensive decontamination 
steps were thoroughly followed to prevent the buildup of contaminating genetic 
material. 
c. Nucleic acid extraction: 
Viral genomic RNA was extracted from the concentrated patient samples 
by using a QIAamp RNA extraction kit (Qiagen GmbH, Hilden, Germany), 
according to the protocol suggested by the manufacturer. Briefly, clinical samples 
were homogenized by vortexing for 30 sec, and 140 µl was used for the extraction 
of viral genomic RNA. The RNA was eluted from the columns with 50 µl of 
elution buffer. The RNA was immediately stored at –25°C after a 10-µl aliquot 
was used for the one step RT-PCR.  
 
d. RT-PCR amplification: 
RT-PCR was performed using QIAGEN OneStep RT-PCR kit (QIAGEN 
GmbH, D-40724 Hilden, Germany). Briefly, 10µl extracted RNA was added to a 
master mix composed of enzyme mix (mixture of heterodimeric recombinant 
reverse transcriptases Omniscript, Sensiscript, and HotStart Taq DNA 
polymerase), 
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400 µM concentrations of each deoxynucleoside triphosphates and the hMPV 
primers sets at 20 pM final concentration (each). Amplification followed the 
optimized profile that was established at Caritas in the thermal cycler (PTC-100; 
MJ Research, Watertown,MA): 42°C for 45 min, 95°C for 7 min, followed by 35 
amplification cycles (denaturation at 95°C for 1 min, annealing at 45°C for 2 min, 
and synthesis at 
72°C for 3 min). Amplification was completed with a prolonged synthesis at 72°C 
for 10 min (Table 5). Amplicons were visualized by ethidium bromide staining 
following electrophoresis on a 2% agarose gel. 
 
Thermal cycler steps Temperature Time 
Step 1- Reverse transcription 50 C 30 mints 
Step 2- Denaturation 1 95 C 15 mints 
Step 3- Denaturation 2 95 C 45 seconds 
Step 4- Annealing  56 C 45 seconds 
Step 5- Synthesis 72 C 1 mint 
Step 6- Amplification GO to step 3 40 times 
Step 7- Prolong synthesis  72 C 10 mints 
Step 8- Storage 4 C For ever 
 
Table 5: protocol used for hMPV detection and amplification 
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2.9 Phylogenetic analysis: 
RT-PCR products were purified directly from the RT-PCR mix using QIA 
quick  PCR purification Kit (Qiagen GmbH, Hilden, Germany), following the 
protocol suggested by the manufacturers, and following their precautions to avoid 
cross-contamination between samples preparations.  Sequenceing using ABI 
PRISM Di- Deoxy Terminator cycle sequencing kit (Applied Biosystems, Foster 
City, CA) was performed at Bethlehem University. Reaction mixtures were 
analyzed on Applied Biosystems model 373 DNA automatic sequencing systems. 
The Sequencer (Gencodes Corporation, Ann Arbor, MI) was used to compare 
nucleotide sequences. Phylogenetic trees were prepared by the nearest neighbor 
analysis using Clustal X with 1,000 bootstraps for each bootstrap. Trees were 
visualized using TreeView or NJ plot. 
 
 
 
 
 
 36 
3. Results 
 
This study was conducted at CBH between the period November 1st 2005 
and October 11th 2006. Nasopharyngeal aspirates were obtained and tested by an 
in-house RT-PCR assay for the presence of hMPV from 790 patients. 
  
3.1 Validation of an RT-PCR assay for the detection of hMPV RNA 
Serial dilution of hMPV RNA was used to validate an RT-PCR assay for 
hMPV RNA detection.  Two sets of primers were evaluated for detecting the 
various strains from all genetic lineages of the virus.  The primers targeted the 
most conserved sequences within the nucleoprotein gene and where designated to 
match all the four genetic lineages of hMPV.  The sensitivity of both primers were 
determined by using serially diluted RNAs obtained from positive hMPV 
reference strain virus 200026583 (CAN-83) passage 3. Identical RNA aliquots 
were used in both the NL-N and the ALT-N assays.  Both assays were able to 
detect viral RNAs from the reference hMPV strain. The NL-N primers were more 
sensitive since they were able to detect 10–6 dilution (Figure 4) whereas the ALT-
N primers detected up to 10–5 hMPV RNA dilution (Figure 5). Moreover, the 
forward primer of the NL-N primer set was paired with the reverse ALT-N primer 
to amplify a 1019 bp PCR product that was used for phylogenetic analysis.  
Amplification of NL-N forward, ALT-N reverse was not as sensitive as the NL-N 
primers set since it was able to detect dilution 10–5 consistently (Figure 6). 
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Figure 4: 2% Gel electrophoresis of hMPV RT-PCR reaction using the NL-N primers on control 
strain serially diluted in water.  Lane 1: 1000 bp marker, lane 2: PCR marker #N3234S, lane 3: 
hMPV RNA dilution 10–1 , lane 4: hMPV RNA dilution 10–2 , lane 5: hMPV RNA dilution 10–3, 
lane 6: hMPV RNA dilution 10–4,  lane 7: hMPV RNA dilution 10–5 ,  lane 8: hMPV RNA dilution 
10–6, and lane 9: Negative Control. 
 
                                                    
 
Figure 5:  2% Gel electrophoresis of hMPV RT-PCR reaction using the ALT-N primers on control 
strain serially diluted in water.  Lane 1: 1000 bp marker, lane 2: PCR marker #N3234S, lane 3:  
hMPV RNA dilution 10–1  , lane 4:  hMPV RNA dilution 10–2  , lane 5:  hMPV RNA dilution 10–3 , 
lane 6: hMPV RNA dilution 10–4 , lane 7: hMPV RNA dilution 10–5  , lane 8:  hMPV RNA dilution 
10–6, lane 9: Negative control. 
  
   
 
Figure 6:  2% Gel electrophoresis of hMPV RT-PCR reaction using the NL-N (from lane 2 to 
lane5) and ALT-N (from lane 7 to lane 11) primers on control strain serially diluted in water.  .  
Lane 1: PCR marker #N3234S, , lane 2:  hMPV RNA dilution 10–3  , Lane 3:  hMPV RNA dilution 
10– 4 , Lane 4:  hMPV RNA dilution 10–5  , Lane 5:  hMPV RNA dilution 10–6 , Lane 6: Negative 
control, Lane 7: hMPV RNA dilution 10–3 , Lane 8: hMPV RNA dilution 10–4  , Lane 9:  hMPV 
RNA dilution 10–5   Lane 10: hMPV RNA dilution 10–6 , Lane 11:  Negative control  , Lane 12: 
1000 bp marker  
            1     2   3    4    5    6     7   8     9   
 
           1    2  3  4   5   6   7   8   9 
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3.2 Specificity of the hMPV NL-N RT-PCR assay 
 
To test the specificity of the NL-N primers designed for the assay, 
genomes from influenza virus A, influenza virus B, RSV, parainfluenza viruses 1, 
2, 3, and adenovirus was used as a template in the assay.  None of the genetic 
material of these viruses cross reacted with the assays primers.   
In addition, we used ATCC bacterial strains that are common in the 
respiratory tract to check for cross reactions.  The strains evaluated were 
Haemophilus influenzae (ATCC 49766), Escherichia coli (ATCC 25922), 
Staphylococcus aureus (ATCC 25923), Pseudomonas aeruginosa (ATCC 27853), 
Streptococcus pyogens (ATCC 19615), Streptococcus pneumoniae (ATCC 
49619), and Moraxella catarrhalis (ATCC 25239) and one clinical bacterial 
isolate (Klebsiella pneumoniae). No cross-reaction was observed by any of the 
bacterial stains evaluated (Figure 7). 
 
 
Figure 7: 2% Gel electrophoresis of hMPV RT-PCR reaction using the NL-N primers on control 
strain serially diluted in water.  Lane 1: 1000 bp marker, Lane 2 hMPV positive control, Lane 3: 
Blank, Lane 4: H. influenzae, Lane 5: Klebsiella, Lane 6: Escherichia coli, Lane 7: Staphylococcus 
aureus, Lane 8: Pseudomonas aeruginosa, Lane 9: Streptococcus pyogens, Lane 10: Streptococcus 
pneumoniae, and Lane 11: Moraxella catarrhalis. Lane 12: Blank, Lane 13: Negative control. 
               
 
         1    2   3    4   5   6   7   8    9   10 11 12 13          
162 bp 
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3.3 Evaluation of the hMPV NL-N RT-PCR assays sensitivity. 
 
The sensitivity of the assay developed in this lab was challenged with 
Quality Control for Molecular Diagnostics (QCMD) external quality control 2006 
batch.  Twelve QCMD RNA samples were analyzed with the in house hMPV RT-
PCR assay. All samples did show the expected results as reported by the 
manufacturer. (Figure 8).   
     
 
 Figure 8: 2% Gel electrophoresis of hMPV RT-PCR reaction using the NL-N primers on control 
strain serially diluted in water.  Lane 1: 1000 bp marker, lane 2: Positive control, lanes 3 up to 14 
are the external quality control 2006 batch. Lane 15: Negative control. 
 
3.4 Prevalence of hMPV RNA in patient samples. 
 
A total number of Patients (N=790) admitted to CBH with acute 
respiratory tract infections between the period November 1st 2005 and October 11 
th
 2006 were enrolled in this study. NPA samples were analyzed by RT-PCR for 
hMPV after amplification of the N gene using the NL-N primers. hMPV RNA 
was detected in 251 (31.7%) of the 790 patients tested.  (Figure 9) illustrate a 
positive and negative patient for hMPV.   
 
  1   2  3   4   5   6   7  8  9  10  11 12  13  14  15  
162 bp 
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Figure 9: 2% Gel electrophoresis of hMPV RT-PCR reaction using the NL-N primers on control 
strain serially diluted in water.  Lane 1: 1000 bp marker, lane 2: Positive control, lanes 3, 4, 5, 6, 7, 
8, 10 are patients samples, Lane 9: H2O (Internal negative control), and Lane 11: Negative control. 
 
3.5 Distribution of hMPV RNA in the Southern Palestinian Districts. 
 
The majority of the patients tested were residents of Bethlehem district 
(63.2%), followed by Hebron (34.3 %), Jerusalem (1.5%), Jericho (0.63%), 
Ramallah (0.25%) and Nablus (0.13%). Of the patients from Bethlehem district 
(N=499), 168 (33.66%) were positive for hMPV, while 78 (28.78%) out of 271 
patients from the Hebron district, where also positive for hMPV. Few of the 
patients enrolled in the study were from Jerusalem district and were positive for 
hMPV. 
The distribution of patients to the different areas of the West Bank is shown in 
table 6   and illustrated in (Figure 10)  
162 bp 
     1     2        3   4    5    6   7    8   9  10         11      
 41 
0
100
200
300
400
Be
thl
ehe
m
He
bro
n
Jer
ich
o
Jer
us
ale
m
Na
blu
s
Ra
m
all
ah
N
u
m
be
r 
o
f P
a
tie
n
ts
Negative Positive
 
 
Figure 10: Distribution of hMPV RNA in the Southern Palestinian Districts.  Blue columns are 
negative patients while green columns are hMPV positive patients. 
 
 
  Negative Positive Total 
Bethlehem 331 168 499 
Hebron 193 78 271 
Jericho 5   5 
Jerusalem 8 4 12 
Nablus 1   1 
Ramallah 1 1 2 
Total 539 251 790 
  
 
Table 6: Distribution of hMPV RNA in the southern Palestinian Districts. 
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 3.6 Distribution of hMPV positive patients by cities and villages. 
Patients admitted to CBH came from many cities and villages from 
Bethlehem and Hebron districts (Figure).  The main areas where hMPV circulated 
during the study period were Bethlehem city (11.77%), Al khader (3.42%), Tque 
(2.91%), Al Doha (3.29%), Beit Jala (4.30), Beit Fajjar (4.81%), and Hebron city 
(5.57%).  The distribution of patients to the different cities and villages of the 
west-Bank is illustrated in (Figure 11). 
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Figure 11: Distribution of patients infected with hMPV by cities and villages.  Red columns are 
negative patients while yellow columns are positive patients. 
 
3.7 Distribution of hMPV by Gender 
Upon analyzing the patient population by gender type, the male to female 
ratio was 1.6:1.  Of the male patient population 64.4% were positive for hMPV 
while 35.6% of the female population was positive for hMPV. The distribution of 
the male to female ration is shown in table 2 and illustrated in (Figure 12) 
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M F
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Overall
M : F
1.7 : 1
hMPV
M : F
1.8 : 1
F (297)
38%
M (493)
62%
F (90)
36%
M (161)
64%
 
Figure 12: Distribution of hMPV by Gender.  Light blue are male patients while blue are female 
patients.  
 
 
3.8 Distribution of positive hMPV patients by age 
 
The patient’s age ranged from one day old new born to 13 years old 
children.  Stratifying the patients by age group, most of patients where less than 
two years old (92.66%) (Table 3) 
The age group for those patients is shown in (Figure 13) the main age of 
hMPV positive babies where less than 6 months of age followed by 6 month age 
group. No difference in age group between male and female patients was noted.  
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Figure 13: Distribution of positive hMPV patients by age.  Blue columns are negative patients 
while green columns are hMPV positive patients.  
 
3.9 Distribution of positive patients by month 
The NPA samples where collected from November 2005 until October 
2006 but mainly during the respiratory disease season.  The hMPV activity was 
between January and July 2006 with two peak activities, one during February 
2006 and a smaller peak activity during April 2006 (Figure 14).   
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Figure 14: Distribution of positive patients by month. Blue columns are negative patients while 
green columns are hMPV positive patients.  
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Upon stratifying hMPV activity by weeks, clearly two hMPV peak activity 
can be noted as shown in (Figure 15).  One hMPV activity was between week 4 
and 14 while the other peak was between week 14 and week 23. 
Interestingly during the second peak an increased activity of RSV virus was noted 
(Figure 16).  Moreover an increase in the double infection rate between RSV and 
hMPV were noted during the second hMPV peak. 
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Figure 15: Distribution of hMPV positive patients by weeks.  Two peaks of hMPV are indicated 
by the arrows. 
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Figure 16: Distribution of hMPV positive patients in red.  Distribution of RSV positive patients in 
blue, while the distribution of hMPV/RSV co-infected patients is shown in yellow. 
 
3.10 Phylogenetic analysis of hMPV positive samples 
 
Of the 251 positive hMPV positive samples 34 (16%) were processed and 
sent to Bethlehem University for sequence analysis of the N gene.  Figure 17 
illustrates a gel electrophoresis of 8 hMPV patient samples PCR products that 
were amplified with the NL-N forward and ALT-R (1019 bp PCR product) and 
sent for sequencing.  Initial processing of the positive patient samples involves 
cleaning the PCR product sample with the Qiagen PCR purification kit as shown 
in (figure 18).  The purified PCR products were then sent to Bethlehem University 
for sequencing using the ALT-N-Reverse primers. 
 
 
 
 
 47 
 
 
Figure 17: 1% Gel electrophoresis of hMPV RT-PCR reaction using the NL-N 
(Forward)/ALT-N (Reveries) primers on control strain serially diluted in water before gel 
purification.  Lane 1: 100 bp marker, lane 2: positive control, Lane: 3 blank, Lanes: 4 – 9, 11 &13 
are hMPV positive samples, Lanes 10 & 12: unamplified patient sample. 
 
  
 
           
Figure 18: 1% Gel electrophoresis of hMPV RT-PCR reaction using the NL-N 
(Forward)/ALT-N (Reveries) primers on control strain serially diluted in water after gel 
purification.  Lane 1: 100 bp marker, lane 2: positive control, Lane: 3 blank, Lanes: 4 – 9, 11 &13 
are hMPV positive samples, Lanes 10 & 12: unamplified patient sample. 
  
Sequence analysis from the 34 isolates had high homology to the reference 
hMPV viral N gene (A1, A2, B1, B2) sequences published in the 
EMBL/GenBank/DDBJ databases.  Depending on the group of hMPV sequenced 
from Southern Palestine, the similarity against the reference strains ranged 
between 95.4% and 96.8%.  Two groups of hMPV appeared to have circulated in 
Southern Palestine during the study period (Figure 16).  High homology (96.8%) 
was noted for one group (N=15) of hMPV from Southern Palestine when 
compared to the reference strain hMPV-A2 (CAN97-83; AY297749), while 100% 
1    2   3    4   5    6    7    8   9   10   11  12 13 
      1     2             3     4     5    6      7     8            9           10     
1019 bp 
1019 bp 
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homology was noted when the same sequence from Palestinian children was 
compared to that from Britain (BJ1887; AY340101), the  positive isolates (N = 
19) where about 95.4% similar to the reference strain the reference strain hMPV-
A2 (A2-CAN97-83(AY297749) however, they were still faraway by 1.4% from 
the closest published sequence from Japan (JPS03-240; AY530095).  This 
suggests a new clade of the hMPV circulated in Southern Palestine.  
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  Figure 19:  Phylogenetic analysis of N-gene of hMPV virus detected in Palestinian children from Southern Palestine. 
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4. Discussion  
One of the biggest challenges in diagnostic microbiology is the 
determination of the causative agent of respiratory tract infections (RTI). This is 
due to the fact that RTI in children and other age groups are caused mainly by 
viruses such as RSV, influenza viruses, parainfluenza viruses, rhinoviruses, and 
coronaviruses (75).  Even with extensive diagnostic testing with highly sensitive 
assays such as PCR and real-time PCR, a substantial portion of RTI cannot be 
attributed to any known pathogen (76). Up to 40% of patients with respiratory 
illnesses during the winter months contain no identifiable viral pathogen (76). At 
Caritas Baby Hospital about 40% of hospitalized patients presenting with upper 
respiratory tract infections do not have a causative agent identified. In part, this 
may reflect the presence of human pathogens similar to the newly discovered one 
(hMPV) or ones that have not been discovered yet. hMPV, the newly discovered 
virus in Dutch children (12) 2001 was found to cause ARTI  in all age groups (13, 
16). Studies have shown that hMPV has circulated in the human for around 50 
years (12). The reason behind this delay in the discovery is due to hMPV’s slow 
replication kinetics and restricted cell line permissivity (12, 13). 
In our study, by using hMPV RNA detection assays, we found hMPV to 
be associated with about 31.8% of the respiratory illness in hospitalized children 
residing in the Southern parts of Palestine.   This high percent of positivity rate is 
one of the highest percents reported to date and might suggest that there was an 
outbreak of hMPV during the study period.  Depending on the study hMPV 
 51 
positivity rates ranged between 1.5% in Australia, to 7.1% in Canada and 25% in 
Italy (13, 19, 23).   
As expected the majority of positive patients came from Bethlehem district 
(33.7%) followed by Hebron District (28.8%).  Indeed, hMPV was detected in all 
cities and villages of Southern Palestine indicating that the virus was capable of 
spreading and one of its genes might have some alterations allowing it to spread 
and cause disease in children (Figure 11). The male to female (1.6:1) ratio of 
positive Palestinian children was similar to that reported by other groups (17).  
Similar to earlier reports on hMPV, the majority of the Palestinian children 
infected were less than 5 years of age, indeed the majority 92% of the patients 
were less than 2 years of age (Figure 13).  Our results are similar to that reported 
by McAdam et al. who showed that the majority of the infected children are less 
than 5 years of age (77). 
Interestingly, the distribution of the patients was unique during the study 
period since the virus had two circulation peaks.  One during February 2006 and 
the other two months later during April 2006 (Figure 14).  The distribution of 
hMPV activity can be seen even more clearly once the virus activity was 
evaluated over weeks (Figure 15).  The circulation of hMPV in Southern Palestine 
was similar to the hMPV circulation reported by Regev et al in Central Israel 
where hMPV main activity was between February and March 2003 (26). 
 52 
One of the interesting features of the study, was the timing of hMPV 
circulation in comparison to the other most common virus, RSV.  A study 
presented by Boivin et al. showed that in Canada, hMPV was mostly active during 
the month of April (17), whereas another Dutch analysis reported the active month 
as being that of December (78).  Unlike other report where they described RSV 
circulation before hMPV (26), in our study, hMPV was detected before RSV 
(Figure 16).  Moreover, we had a large number of double infections during the 
second wave of hMPV (Figure 16).  During the study period 50 patients (6.3%) 
had double infection between hMPV and RSV. 
Sequence analysis of the hMPV reference genome shows that it has two 
main genetic lineages (A and B) representing two sereotypes. Each of the latter 
comprises two sub lineages (A1, A2, B1 and B2) (53, 79).  Phyloganetic analysis 
of the N-gene of 14% of the positive Palestinian patients amplified hMPV PCR 
products showed that two serotypes of hMPV A lineage circulated in Southern 
Palestine, while no isolates of B lineage was detected.  Indeed, they two serotypes 
were not the same that that reported for the reference strains.  Of the samples 
analyzed, 43% of the sequenced hMPV samples belonged to a novel serotype of 
the lineage A (Figure 19).  Upon determining the homology of the newly 
discovered serotype, 95% homology was observed.  Having this 5% difference 
from the 377 base pair sequences allows to hypothesis that we are dealing with a 
new serotype and that A lineage has three serotypes and not two.  Moreover, a 
very recent report from Germany hypothesized that there are three serotypes for 
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A2 hMPV lineage (80).  Unfortunately, they have not published enough 
sequenced so we can compare the sequence from Palestine with their sequence.       
One of the important outcomes that we are pursuing is the clinical 
presentation of the children infected with hMPV and the ones co-infected with 
hMPV and RSV.  Our initial investigation revealed that the patients that were 
infected with hMPV presented with similar symptoms as RSV.  Compiling the 
data is still in progress and it will be of interest to compare the patients that are 
infected with the two different serotypes of hMPV. Over the world people have 
reported similar clinical presentation between hMPV and RSV (13, 81).  In 
addition, it will of great interest to see the severity of respiratory illness in patients 
co-infected with hMPV and RSV.   
In conclusion, this study is the first report that describes the viral genetic 
lineages and the prevalence of hMPV infections in Southern Palestine. The 
discovery of hMPV and its incorporation to routine diagnostic procedures has 
allowed us to identify the cause of a significant number of respiratory tract 
infections (31.8%). More upper RTI will be identified when sensitive diagnostic 
techniques are developed and routinely applied from testing common respiratory 
pathogens such as rhinoviruses, and coronavirus. However, there still remain a 
significant number of infections that have still not been associated with any known 
pathogen.   
It is of utmost importance for our Palestinian physicians to know that 
hMPV is present in the Palestine.  Not only that, but it can cause large outbreaks 
 54 
as shown in our study.  Our study clearly showed that hMPV diagnostic assays 
should be made available for our physicians.  Home brew assays for the detection 
of hMPV are not expensive and hospitals in Palestine should bring these 
laboratory diagnostic techniques to their laboratories.  This will help them in 
controlling the usage of antibiotics thus indirectly helping in reducing the 
emergence of drug resistant bacteria such as multidrug resistant Klebsiella 
pneumoniae, Acinitobacter, Streptococcus pneumoniae and methicillin resistant 
Staphylococcus aureus.  Moreover, in severe hMPV infections, physicians might 
be able to use the antiviral drug Ribavirin as a therapy to help the infected patients 
get over the hMPV infection since hMPV is a close relative to RSV and RSV is 
well know to respond to Ribavirin.  Finally, researchers should invest more time 
and effort in developing a vaccine against hMPV in order to protect the children 
less than 5 years of age.  
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Conclusions and Recommendations: 
1. hMPV circulated in Southern Palestine and preceded the RSV season. 
2. hMPV frequency in Palestine during the study period was the highest rate 
reported worldwide to date (31.8%). 
3.  hMPV major activity was during January and April 2006. 
4. 95% of hMPV infected children were less than 2 years of age. 
5. hMPV A2 lineage circulated in Southern Palestine during the study period. 
6.  Our Phylogenetic analysis proposes the discovery of a new A2 sub-lineage. 
7. Careful clinical evaluation of infected children should be performed to compare 
the clinical presentations of hMPV and RSV. 
8. Role of hMPV/RSV double infection in patient hospitalization should be 
evaluated. 
9. Evaluation of the clinical presentation of infected children with the two lineages 
should be determined. 
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